Platelet lncRNA as a biomarker for early screening of lung adenocarcinoma: a preliminary study
Journal Title: Chinese Journal of Blood Transfusion - Year 2024, Vol 37, Issue 3
Abstract
Objective To explore the diagnostic value of platelet long non-coding RNA (lncRNA) as a biomarker for early screening of lung adenocarcinoma (LUAD). Methods The GSE183635 and GSE89843 datasets, which contained the platelet transcriptome of LUAD and healthy controls, were used for differential analysis, and the intersection of the differentially expressed lncRNA(DElncRNA) of the two datasets was taken. The expression levels of DElncRNA in LUAD tissues and normal control tissues were analyzed using GEPIA2. The expression levels of LINC01088 in platelets of 51 healthy controls and 54 LUAD patients were detected by quantitative Real-time PCR (qRT-PCR), and the diagnostic ability of each index was evaluated by ROC curve. Results 8 DElncRNAs and 1 265 DElncRNAs were obtained from GSE183635 and GSE89843 datasets, respectively. The key DElncRNA LINC01088 was selected after intersection. GEPIA2 analysis showed that the expression level of LINC01088 in LUAD tissues was lower than that in normal lung tissues (P<0.05). Platelet LINC01088 was significantly downregulated in patients with LUAD and early-stage LUAD than in healthy controls(P<0.001). The area under the curve (AUC) of platelet LINC01088 in the diagnosis of LUAD was 0.755, the sensitivity was 81.1%, and the specificity was 67.9%. The AUC for early LUAD diagnosis was 0.727, the sensitivity was 80.0%, and the specificity was 67.9%. The AUC of the combined diagnostic model composed of platelet LINC01088 and carcinoembryonic antigen (CEA) for LUAD diagnosis was 0.807, the sensitivity was 89.2%, and the specificity was 71.4%. The AUC for early LUAD was 0.770, the sensitivity was 86.7%, and the specificity was 71.4%. The combined diagnostic model of platelet LINC01088 and CEA was superior to CEA in the diagnosis of LUAD and early LUAD (Z=-2.288, -2.34, both P<0.05). Conclusion LINC01088 is down-regulated in platelets of LUAD patients. Platelet LINC01088 may be a biomarker for early screening and diagnosis of LUAD.
Authors and Affiliations
Bowen XIONG, Xing YIN, Huaichao LUO, Yu LIU
Keywords
Related Articles
- EP ID EP738778
- DOI 10.13303/j.cjbt.issn.1004549x.2024.03.005
- Views 47
- Downloads 0
Molecular genetic analysis and identification of novel alleles of ABO subtypes
Objective To study the molecular mechanism of 95 samples of serological ABO subtypes. Methods A total of 95 samples with discrepancy between forward and reverse blood grouping were subjected to serological confirmation,...
Research progress in clinical application of lymphoplasmapheresis in immune-related diseases
Lymphoplasmapheresis(LPE) is a combination of plasma exchange and lymphocyte separation technology. It can not only remove autoimmune antibodies, but also remove the immune active cells producing these antibodies. At the...
Investigation of human parvovirus B19 infection in college students
Objective To investigate the prevalence of human parvovirus B19 (B19V) infection among college students, so as to provide reference for the development of blood donor screening strategies and blood supply policies. Metho...
Analysis of platelet apheresis transfusion trends in Suzhou from 2017-2022
[Objective] To investigate the clinical characteristics of patients who underwent multiple platelet transfusions (≥2 times) in Suzhou over the past 5 years (2017-2022), as to provide new insights for patients requiring l...
Matrix effect on the determination of Potency in Recombinant Coagulation Factor Ⅷ for injection
Objective To investigate the matrix effect on the determination of potency in Recombinant Human Coagulation Factor Ⅷ for Injection (rFⅧ). Methods Two different detection matrices were used to establish two methods for de...